RxDoctor Payments Data

Lisa Miconi-Correa

Family · Ogden, UTNPI 1376830414

Payments from drug & device makers

$5,033in general payments, 2019–2025

Across 309 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$638
  • Astellas Pharma US Inc$330
  • AstraZeneca$269
  • Amarin Pharma, Inc.$268
  • Pfizer$238
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,83396%
  • Education$2004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,033 in reported general payments places this provider in the 90th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$102,606
Medicare patients
316
Services billed
7,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$69,757
EliquisApixaban44$53,956
FarxigaDapagliflozin Propanediol32$42,814
XareltoRivaroxaban37$37,867
VraylarCariprazine Hcl24$36,351
MounjaroTirzepatide29$34,379
MyrbetriqMirabegron19$24,264
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$14,457
JardianceEmpagliflozin11$13,401
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,721
MovantikNaloxegol Oxalate15$8,768
Breo ElliptaFluticasone/Vilanterol13$8,292
Advair HfaFluticasone Propion/Salmeterol13$4,733
Levothyroxine Sodium379$4,407
Omeprazole215$4,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$84$69,75755 claims
PfizerEliquis$238$53,95644 claims
AstraZenecaFarxiga$269$42,81432 claims
AbbVieVraylar, Synthroid$1,389$38,31856 claims
Johnson & JohnsonXarelto$198$37,86737 claims
Lilly USA, LLCMounjaro$638$34,37929 claims
Astellas Pharma US IncMyrbetriq$330$24,26419 claims
GSKTrelegy Ellipta, Breo Ellipta$170$20,01327 claims
Boehringer IngelheimJardiance$87$13,40111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,460 family providers in Utah.

Other family in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →